Am J Psychiatry 159:1731-1737, October 2002
© 2002 American Psychiatric Association
A Randomized Trial of Sertraline as a Cessation Aid for Smokers With a History of Major Depression
Lirio S. Covey, Ph.D.,
Alexander H. Glassman, M.D.,
Fay Stetner, M.S.,
Sarah Rivelli, M.D., and
Kurt Stage, M.D.
OBJECTIVE: Evidence that major depression can be a significant hindrance to smoking cessation prompted this examination of the usefulness of sertraline as a cessation aid for smokers with a history of major depression. Specifically, sertraline’s efficacy for smoking abstinence and its effects on withdrawal symptoms were evaluated. METHOD: The study design included a 1-week placebo washout, a 9-week double-blind, placebo-controlled treatment phase followed by a 9-day taper period, and a 6-month drug-free follow-up. One hundred thirty-four smokers with a history of major depression were randomly assigned to receive sertraline (N=68) or matching placebo (N=66); all received intensive individual cessation counseling during nine clinic visits. RESULTS: Sertraline treatment produced a lower total withdrawal symptom score and less irritability, anxiety, craving, and restlessness than placebo. However, the abstinence rates did not significantly differ between treatment groups: 28.8% (19 of 66) for placebo and 33.8% (23 of 68) for sertraline at the end of treatment and 16.7% (11 of 66) for placebo and 11.8% (eight of 68) for sertraline at the 6-month follow-up. No moderating effects of single or recurrent major depression, depressed mood at baseline, nicotine dependence level, or gender were observed. CONCLUSIONS: Sertraline did not add to the efficacy of an intensive individual counseling program in a double-blind, placebo-controlled study. However, given that the end-of-treatment abstinence rate for the placebo group was much higher than expected, it is unclear whether a ceiling effect of the high level of psychological intervention received by all subjects prevented an adequate test of sertraline.
This article has been cited by other articles:
|
|
|
|
 
P. Aveyard, C. Johnson, S. Fillingham, A. Parsons, and M. Murphy
Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial
BMJ,
May 31, 2008;
336(7655):
1223 - 1227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ranney, C. Melvin, L. Lux, E. McClain, and K. N. Lohr
Systematic Review: Smoking Cessation Intervention Strategies for Adults and Adults in Special Populations
Ann Intern Med,
December 5, 2006;
145(11):
845 - 856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. McFall, A. J. Saxon, C. E. Thompson, D. Yoshimoto, C. Malte, K. Straits-Troster, E. Kanter, X.-H. A. Zhou, C. M. Dougherty, and B. Steele
Improving the Rates of Quitting Smoking for Veterans With Posttraumatic Stress Disorder
Am J Psychiatry,
July 1, 2005;
162(7):
1311 - 1319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Zellweger, R. H. Osterwalder, W. Langewitz, and M. E. Pfisterer
Coronary artery disease and depression
Eur. Heart J.,
January 1, 2004;
25(1):
3 - 9.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs.,
January 1, 2003;
6(1):
e1 - 1.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
